Kane Biotech Inc. (CVE:KNE – Get Free Report) rose 33.3% during trading on Wednesday . The stock traded as high as C$0.05 and last traded at C$0.04. Approximately 1,259,050 shares were traded during trading, an increase of 963% from the average daily volume of 118,486 shares. The stock had previously closed at C$0.03.
Kane Biotech Price Performance
The company has a debt-to-equity ratio of -331.42, a current ratio of 0.80 and a quick ratio of 0.39. The firm has a market cap of C$6.65 million, a P/E ratio of -0.44 and a beta of 0.29. The stock’s 50-day simple moving average is C$0.04 and its two-hundred day simple moving average is C$0.04.
About Kane Biotech
Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections.
Featured Stories
- Five stocks we like better than Kane Biotech
- What Makes a Stock a Good Dividend Stock?
- Why AutoZone’s Stock Drop Could Be a Golden Buying Opportunity
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Ollie’s Bargain Outlet Hits Rock-Bottom in Q4: Buy the Dip?
- What Are Earnings Reports?
- Insiders Are Selling These 3 Stocks—Here’s Why
Receive News & Ratings for Kane Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kane Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
